Sequential Treatment of Severe Atopic Dermatitis with Cyclosporin A and Low-Dose Narrow-Band UVB Phototherapy

Dermatology ◽  
2002 ◽  
Vol 204 (3) ◽  
pp. 252-254 ◽  
Author(s):  
V. Brazzelli ◽  
F. Prestinari ◽  
M.G. Chiesa ◽  
R.G. Borroni ◽  
M. Ardigò ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cyclosporin A ◽  
Low Dose ◽  
Narrow Band ◽  
Sequential Treatment ◽  
Severe Atopic Dermatitis ◽  
Uvb Phototherapy

Narrow-band UVB phototherapy for severe atopic dermatitis

1996 ◽  
Vol 135 (2) ◽  
pp. 332-332 ◽  
Author(s):  
M. J. Hudson-Peacock ◽  
B.L. Diffey ◽  
P. M. Farr
Keyword(s):  
Atopic Dermatitis ◽  
Narrow Band ◽  
Severe Atopic Dermatitis ◽  
Uvb Phototherapy

A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis

Dermatology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Cesare Tomasi ◽  
Irene Calzavara-Pinton ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Narrow Band ◽  
Ultraviolet B ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Treatment Regimens ◽  
Short Course ◽  
Receive Treatment ◽  
Uvb Phototherapy

<b><i>Background:</i></b> Since the best clinical response to dupilumab is achieved after 12–16 weeks, a combination therapy at the beginning of the treatment could be a helpful strategy to reach a faster response in patients with severe atopic dermatitis (AD). <b><i>Objectives:</i></b> To quantify the benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B (NB-UVB) phototherapy. <b><i>Methods:</i></b> In the present pilot study adult patients suffering from severe AD were enrolled with a 2:1 ratio to receive treatment with dupilumab alone or dupilumab plus NB-UVB phototherapy, for 12 weeks. After the twelfth week, all patients received dupilumab only. A follow-up visit took place after 16 weeks. Both clinician-oriented and patient-oriented scores were assessed at baseline (T0) and after 4 (T1), 12 (T2) and 16 (T3) weeks. <b><i>Results:</i></b> Forty-five adult patients were enrolled in the study. Both treatment regimens were well tolerated and very effective on all measured scores (EASI, SCORAD, BSA, NRS of itching, NRS of sleep loss, DLQI, POEM and HADS), but the combined regimen led to a more robust clinical improvement of lesions and relief of symptoms after 4 weeks. However, after 12 and 16 weeks, the additional therapeutic effect of phototherapy weakened. <b><i>Conclusion:</i></b> NB-UVB phototherapy can provide a faster remission of severe AD in the first few weeks of dupilumab therapy.

Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: Clinical and immunological effects

2001 ◽  
Vol 12 (4) ◽  
pp. 216-223 ◽  
Author(s):  
Rita Bunikowski ◽  
Doris Staab ◽  
Fatima Kussebi ◽  
Matthias Bräutigam ◽  
Gottfried Weidinger ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Cyclosporin A ◽  
Low Dose ◽  
Severe Atopic Dermatitis ◽  
Immunological Effects

scholarly journals Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate and Severe Atopic Dermatitis of the Adult

2018 ◽  
Vol 64 (1) ◽  
pp. 17-21
Author(s):  
Gyula Laszlo Fekete ◽  
László Fekete
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Systemic Therapy ◽  
Systemic Corticosteroid ◽  
Corticosteroid Treatment ◽  
Serum Levels ◽  
Severe Atopic Dermatitis ◽  
Therapeutic Trial ◽  
Group I ◽  
Uvb Phototherapy

AbstractObjectives: The aim of this clinical and therapy study was to evaluate the efficacy of NB-UVB phototherapy versus systemic therapy in moderate-to-severe atopic dermatitis of the adult.Material and methods: The subjects of the study were divided into two groups of 25 adult patients with moderate and severe atopic dermatitis according to the inclusion criteria. The first group of 25 patients were treated with systemic corticosteroids while the second group of 25 patients were treated with NB-UVB phototherapy. At the end of the study, after all the data were centralized, we performed a statistical analysis of the results, comparing the two groups as well as the efficacy of the different therapies.Results: In group I the clinical efficacy of the systemic corticosteroid treatment was achieved, on average, at 4 weeks in patients with moderate atopic dermatitis and at 6 weeks in patients with severe atopic dermatitis. In group II the clinical effecacy of NB-UVB phototherapy was achieved, on average, at 6 weeks for patients with moderate atopic dermatitis and at 8 weeks for those with the severe form. In both groups, the total IgE serum levels were elevated at the beginning, and they became normal throughout the clinical improvement. Remarkable therapy-related side effects were found in the first study group.Conclusion: We conclude that NB-UVB phototherapy had similar efficacy in treating moderate-to-severe atopic dermatitis with minimal side effects compared to systemic corticosteroid therapy.

Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: A pilot study

2013 ◽  
Vol 40 (3) ◽  
pp. 207-210 ◽  
Author(s):  
Hyok-Bu KWON ◽  
Byung-Jin AHN ◽  
Yunseok CHOI ◽  
Sang Y. JIN ◽  
Kyung A. CHEONG ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Cyclosporin A ◽  
Therapeutic Effect ◽  
Low Dose

scholarly journals An 8-Year-Old Child with Delayed Diagnosis of Netherton Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Alexander K. C. Leung ◽  
Benjamin Barankin ◽  
Kin Fon Leong
Keyword(s):  
Atopic Dermatitis ◽  
Early Diagnosis ◽  
Marked Improvement ◽  
Low Dose ◽  
Delayed Diagnosis ◽  
Severe Atopic Dermatitis ◽  
Netherton Syndrome

We report an 8-year-old boy with Netherton syndrome who was misdiagnosed and treated as severe atopic dermatitis. The diagnosis of Netherton syndrome was not made until the child was 8 years of age. We discuss the pitfalls in the diagnosis and alert physicians to the proper and early diagnosis of this syndrome. The child was treated with a low dose (0.25 mg/kg) of oral acitretin and a topical moisturizer with marked improvement of his skin and pruritus in 2 months. At 6-month follow-up, the skin was almost clear of erythema and scaling, and the hair was longer and stronger. The dose of acitretin was reduced to 0.12 mg/kg for another 6 months and then discontinued.

Sign in / Sign up

Export Citation Format

Share Document